# Sanmed Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sanmed-biotech

- Industry: Biotechnology
- Headquarters: Zhuhai, China
- Website: www.sanmedbio.com
- Total disclosed funding: $46M
- Latest round: Series B (Apr 2, 2021)
- Investors on record: 1

## About

Sanmed Biotech, based in Zhuhai, China, specializes in liquid biopsy technologies aimed at enhancing cancer detection and management, particularly lung cancer, through innovative diagnostic solutions.Founded in 2016 in Zhuhai, China, Sanmed Biotech focuses on liquid biopsy technologies. The company has raised a total of RMB 300 million through 2 funding deals, the most recent being a Series B round in April 2021 led by China Merchants Capital.Zhuhai Sanmed Biological Diagnostics Co., Ltd. specializes in liquid biopsy technologies aimed at enhancing the early detection and management of cancer, particularly lung cancer. The company's core product, the LiquidBiopsy system, is an automated platform that efficiently isolates and enriches circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from blood samples. This technology enables precise molecular diagnostics without the need for whole genome amplification, allowing for seamless integration with various downstream sequencing techniques. The primary end users of these products include healthcare providers and institutions looking to improve cancer patient outcomes through early intervention and targeted treatments. The company’s products and services are marketed primarily in China, with aspirations to expand into other international markets, particularly those in Portuguese-speaking countries, aligning with its strategic collaborations.Zhuhai Sanmed Biological Diagnostics operates through direct sales of its liquid biopsy systems and associated diagnostic services to hospitals and research institutions. Revenue is generated from the sale of its flagship LiquidBiopsy system, which is complemented by ongoing service agreements and consumables linked to the technology. The transaction structure typically involves direct sales to healthcare providers, along with partnerships that facilitate broader distribution and usage of its products. The company’s pricing strategy is designed to align with the healthcare sector’s needs, emphasizing cost-effectiveness and value for early cancer detection solutions. This structured approach not only enhances the accessibility of its diagnostic tools but also supports the company’s growth in a competitive market focused on innovative healthcare solutions.In April 2021, Sanmed Biotech raised RMB 300 million in Series B funding to further develop its liquid biopsy technologies. The company plans to launch new diagnostic products aimed at improving cancer detection capabilities by the end of 2023. Additionally, Sanmed Biotech is targeting expansion into Portuguese-speaking countries to enhance its market presence. The recent funding will support these initiatives, enabling the company to invest in product development and market entry strategies.

## Funding rounds

- Series B, Apr 2, 2021, $46M — China Merchants Capital

## Investors

- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series B